CMBRS23057 / Weiss / A012103
Basic Study Information
Purpose:
The phase III trial compares the effect of pembrolizumab to observation for the treatment
of patients with early-stage triple-negative breast cancer who achieved a pathologic
complete response after preoperative chemotherapy in combination with pembrolizumab.
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. This trial may help researchers determine if observation will
result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative
breast cancer patients who achieve pathologic complete response after preoperative
chemotherapy with pembrolizumab.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Anna Weiss
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search